Cargando…
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
AIMS: Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) receptor (LDLR) fate, has emerged as a promising therapeutic target for atherosclerotic cardiovascular diseases. However, the precise mechanism by which PCSK9 regulates the internali...
Autores principales: | Jang, Hyun-Duk, Lee, Sang Eun, Yang, Jimin, Lee, Hyun-Chae, Shin, Dasom, Lee, Hwan, Lee, Jaewon, Jin, Sooryeonhwa, Kim, Soungchan, Lee, Seung Ji, You, Jihye, Park, Hyun-Woo, Nam, Ky-Youb, Lee, Sang-Hak, Park, Sahng Wook, Kim, Jin-Soo, Kim, Sang-Yeob, Kwon, Yoo-Wook, Kwak, Soo Heon, Yang, Han-Mo, Kim, Hyo-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945527/ https://www.ncbi.nlm.nih.gov/pubmed/31419281 http://dx.doi.org/10.1093/eurheartj/ehz566 |
Ejemplares similares
-
Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022) -
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017) -
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020) -
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
por: Shafiq, Muhammad, et al.
Publicado: (2020)